Affiliation:
1. Tufts Center for the Study of Drug Development (CSDD), Tufts University School of Medicine 75 Kneeland Street, Suite 1100, Boston, MA 02111, USA
Abstract
Four challenges to the adoption of personalized medicine were identified in the mid-2000s – adherence to the blockbuster model, the lack of a supportive regulatory environment, the dysfunctional payment system and physician barriers. In this article, we report on our study findings based on interviews with 24 senior executives from leading drug and diagnostics companies to assess progress made in addressing those challenges over the last decade. Overall, we found that even with payer pushback and adjusting to new business models, the majority of developers expected their business to increase over the next 5 years. Several factors that unexpectedly helped to shape the personalized medicine landscape, such as the growth of support in genomic medicine from the public sector, are also discussed.
Subject
Pharmacology,Molecular Medicine,General Medicine
Reference16 articles.
1. Where is personalized medicine in industry heading?
2. Audette J. Introducing the Personalized Medicine Scorecard™: Drug Companies Edition. www.amplion.com/biomarker-trends/these-are-the-drug-companies-driving-innovation-in-precision-medicine.
3. FiercePharma. The Companion Diagnostics (CDx) Market Forecast 2015–2025 (2015). www.fiercepharma.com.